Over the past year there were no insider purchases at UroGen Pharma Ltd.. Three insiders sold roughly $4.8 million instead.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Looking at the quarterly pattern: 7 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters. On the institutional side, 189 funds reported holding URGN at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | Degnan Chris | CFO | Sell | 2,202 | $36.69 | $81K | SEC |
| Sep 9, 2026 | Schoenberg Mark | Executive Officer | Sell | 871 | $42.92 | $37K | SEC |
| Sep 9, 2026 | Smith Jason Drew | Executive Officer | Sell | 1,519 | $42.54 | $65K | SEC |
| Aug 24, 2026 | Schoenberg Mark | Executive Officer | Sell | 60,677 | $47.05 | $2.9M | SEC |
| Jul 10, 2026 | Schoenberg Mark | Executive Officer | Sell | 10,000 | $40.00 | $400K | SEC |
| Jun 24, 2026 | Schoenberg Mark | Executive Officer | Sell | 10,000 | $35.01 | $350K | SEC |
| Jun 9, 2026 | Schoenberg Mark | Executive Officer | Sell | 5,222 | $27.30 | $143K | SEC |
| May 11, 2026 | Schoenberg Mark | Executive Officer | Sell | 10,000 | $30.00 | $300K | SEC |
| Feb 11, 2026 | Smith Jason Drew | Executive Officer | Sell | 3,217 | $19.69 | $63K | SEC |
| Feb 11, 2026 | Smith Jason Drew | Executive Officer | Sell | 1,608 | $19.69 | $32K | SEC |
| Feb 11, 2026 | Smith Jason Drew | Executive Officer | Sell | 2,654 | $19.69 | $52K | SEC |
| Feb 4, 2026 | Schoenberg Mark | Executive Officer | Sell | 1,843 | $19.69 | $36K | SEC |
| Feb 4, 2026 | Schoenberg Mark | Executive Officer | Sell | 3,686 | $19.69 | $73K | SEC |
| Feb 4, 2026 | Schoenberg Mark | Executive Officer | Sell | 1,844 | $19.69 | $36K | SEC |
| Nov 20, 2025 | Schoenberg Mark | Executive Officer | Sell | 10,000 | $25.00 | $250K | SEC |
In the last 12 months UroGen Pharma Ltd. insiders made open-market purchases worth about $0 and sales worth about $4.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in URGN was filed on 2026-10-09.
189 investment managers reported holding URGN in SEC Form 13F filings for Q2 2026.
No congressional trades in URGN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).